Back
Open Access

Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD.

Session: Clinical Update on Managing Hypertriglyceridaemia with Omega-3 Fatty Acid Icosapent Ethyl
Topic: Cardiovascular Risk Assessment
Speaker: Professor P. Steg (Paris, FR)
Sponsored by Amarin Pharma, Inc.
Event: ESC Congress 2020

Congress Presentation

About the speaker

Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)
63 presentations
10 followers

4 more presentations in this session

Welcome and Introductions, Program Overview.

Speaker: Professor P. Steg (Paris, FR)

Access
Video
Thumbnail

Hypertriglyceridaemia as a Causal Factor and Target for Therapy.

Speaker: Professor B. Nordestgaard (Copenhagen, DK)

Access
Video
Thumbnail

Practical Considerations on Using Omega-3 Fatty Acids to Prevent ASCVD.

Speaker: Professor B. Nordestgaard (Copenhagen, DK)

Access
Video
Thumbnail

Live Q&A and Adjourn.

Speaker: Professor P. Steg (Paris, FR) Professor B. Nordestgaard (Copenhagen, DK)

Access
Video
Thumbnail

Access the full session

Clinical Update on Managing Hypertriglyceridaemia with Omega-3 Fatty Acid Icosapent Ethyl

Speakers: Professor P. Steg, Professor P. Steg, Professor B. Nordestgaard, Professor B. Nordestgaard, Professor P. Steg...
Access
Video
Thumbnail

About the event

Image

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb